University of Wisconsin-Madison, Madison, USA.
Claude Bernard University Lyon 1, Lyon, France.
BMC Public Health. 2024 Jan 7;24(1):112. doi: 10.1186/s12889-023-17563-x.
Psychoactive drug combinations are increasingly contributing to overdose deaths among White and Black Americans. To understand the evolving nature of overdose crisis, inform policies, and develop tailored and equitable interventions, this study provides a comprehensive assessment of polysubstance mortality trends by race and sex during the opioid epidemic.
We used serial cross-sectional US mortality data for White and Black populations from 1999 through 2018 to calculate annual age-adjusted death rates (AADR) involving any opioid, opioid subtypes, benzodiazepines, cocaine, psychostimulants, or combinations of these drugs, stratified by race and sex. Trend changes in AADR were analyzed using joinpoint regression models and expressed as average annual percent change (AAPC) during each period of the three waves of the opioid epidemic: 1999-2010 (wave 1), 2010-2013 (wave 2), and 2013-2018 (wave 3). Prevalence measures assessed the percent co-involvement of an investigated drug in the overall death from another drug.
Polysubstance mortality has shifted from a modest rise in death rates due to benzodiazepine-opioid overdoses among White persons (wave 1) to a substantial increase in death rates due to illicit drug combinations impacting both White and Black populations (wave 3). Concurrent cocaine-opioid use had the highest polysubstance mortality rates in 2018 among Black (5.28 per 100,000) and White (3.53 per 100,000) persons. The steepest increase in death rates during wave 3 was observed across all psychoactive drugs when combined with synthetic opioids in both racial groups. Since 2013, Black persons have died faster from cocaine-opioid and psychostimulant-opioid overdoses. Between 2013 and 2018, opioids were highly prevalent in cocaine-related deaths, increasing by 33% in White persons compared to 135% in Blacks. By 2018, opioids contributed to approximately half of psychostimulant and 85% of benzodiazepine fatal overdoses in both groups. The magnitude and type of drug combinations with the highest death rates differed by race and sex, with Black men exhibiting the highest overdose burden beginning in 2013.
The current drug crisis should be considered in the context of polysubstance use. Effective measures and policies are needed to curb synthetic opioid-involved deaths and address disparate mortality rates in Black communities.
精神活性药物的联合使用正在导致白人和黑人群体的药物过量死亡人数不断增加。为了了解药物过量危机的演变性质,为政策提供信息,并制定有针对性和公平的干预措施,本研究通过种族和性别,对阿片类药物流行期间涉及任何阿片类药物、阿片类药物亚型、苯二氮䓬类药物、可卡因、苯丙胺类兴奋剂或这些药物组合的多物质死亡率趋势进行了全面评估。
我们使用了 1999 年至 2018 年美国白人和黑人的连续横断面死亡数据,计算了涉及任何阿片类药物、阿片类药物亚型、苯二氮䓬类药物、可卡因、苯丙胺类兴奋剂或这些药物组合的多物质死亡率,按种族和性别分层。使用连接点回归模型分析 AADR 变化趋势,并表示为阿片类药物流行三个波次期间每个时期的平均年百分变化(AAPC):1999-2010 年(波 1)、2010-2013 年(波 2)和 2013-2018 年(波 3)。流行率指标评估了所研究药物在另一种药物总体死亡中共同涉及的百分比。
多物质死亡率已从白人因苯二氮䓬类药物-阿片类药物过量而导致的死亡率适度上升(波 1)转变为因影响白人和黑人的非法药物组合而导致的死亡率大幅上升(波 3)。2018 年,黑人(每 10 万人 5.28 人)和白人(每 10 万人 3.53 人)人群中同时使用可卡因和阿片类药物的多物质死亡率最高。在两个种族群体中,当与合成阿片类药物联合使用时,所有精神活性药物的死亡率在波 3 期间都出现了最急剧的上升。自 2013 年以来,黑人因可卡因-阿片类药物和苯丙胺-阿片类药物过量而死亡的速度更快。2013 年至 2018 年间,阿片类药物在与可卡因相关的死亡中高度流行,白人的流行率增加了 33%,而黑人则增加了 135%。到 2018 年,阿片类药物约占两组中苯丙胺类兴奋剂和 85%苯二氮䓬类药物致命过量的一半。不同种族和性别的最高死亡率的药物组合的规模和类型有所不同,黑人男性从 2013 年开始表现出最高的过量负担。
目前的药物危机应结合多物质使用情况来考虑。需要采取有效的措施和政策来遏制与合成阿片类药物相关的死亡,并解决黑人社区的差异死亡率问题。